Mouse Genome Informatics
cn1
    Abcb8tm1Hard/Abcb8tm1Hard
Tg(Myh6-cre/Esr1*)1Jmk/0

involves: FVB
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
cardiovascular system
• subcellular disorganization, with accumulation of vacuoles, mitochondria showing diversity in size, profoundly disrupted alignment, and a rounder and more densely packed appearance after tamoxifen treatment
• loss of mitochondrial cristae and smaller average mitochondria size after tamoxifen treatment
• elevated mitochondrial iron content but not heme levels 4 weeks after tamoxifen treatment
• distorted and wavy myofiber architecture 4 weeks after tamoxifen treatment
• mitochondrial deformities accompanied by electron-dense material are present after tamoxifen treatment
• 8 weeks after tamoxifen treatment
• increased left ventricular diastolic diameter at 8 weeks after tamoxifen treatment
• 8 weeks after tamoxifen treatment
• elevated lipid peroxidation and reactive oxygen species after tamoxifen treatment
• as early as 4 weeks after tamoxifen treatment
• reduced heart pump function as measured by fractional shortening and ejection fraction 4 and 8 weeks after tamoxifen treatment
• decreased strength of contraction (dP/dtmax) at 8 weeks after tamoxifen treatment
• decreased relaxation (dP/dtmin) at 8 weeks after tamoxifen treatment
• lower end systolic pressure at 8 weeks after tamoxifen treatment
• mild after tamoxifen treatment

homeostasis/metabolism
• elevated mitochondrial iron content but not heme levels 4 weeks after tamoxifen treatment

muscle
• distorted and wavy myofiber architecture 4 weeks after tamoxifen treatment
• mitochondrial deformities accompanied by electron-dense material are present after tamoxifen treatment
• reduced heart pump function as measured by fractional shortening and ejection fraction 4 and 8 weeks after tamoxifen treatment
• decreased strength of contraction (dP/dtmax) at 8 weeks after tamoxifen treatment
• decreased relaxation (dP/dtmin) at 8 weeks after tamoxifen treatment
• mild after tamoxifen treatment